NASDAQ:APRE

Aprea Therapeutics Q1 2025 Earnings Results & Report

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$0.66 versus the -$0.6543 consensus estimate, while revenue was $162 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Aprea Therapeutics EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.6543
Beat/Miss
Missed by -$0.0057
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
$162 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Q1 2025 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.66 per share for Q1 2025, missing the consensus estimate of -$0.6543. The report was announced on Wednesday, May 14, 2025.

Aprea Therapeutics reported revenue of $162 thousand for Q1 2025.

Aprea Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile